Evidence map›Paper›PMID 26211743›Full record

ArticleCancer science2015

Downregulation of TBXAS1 in an iron-induced malignant mesothelioma model.

Daisuke Minami, Nagio Takigawa, Yuka Kato, Kenichiro Kudo, Hideko Isozaki, Shinsuke Hashida, Daijiro Harada, Nobuaki Ochi, Masanori Fujii, Toshio Kubo and 8 more

Open access · goldAbstract read
In one paragraph

Article in Cancer science, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 1 country.

Daisuke MinamiDepartment of Hematology, Oncology and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
Nagio TakigawaDepartment of General Internal Medicine, Kawasaki Medical School, Okayama, Japan.
Yuka KatoDepartment of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Kenichiro KudoDepartment of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Hideko IsozakiDepartment of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Shinsuke HashidaDepartment of Thoracic, Breast and Endocrinological Surgery, Okayama University Hospital, Okayama, Japan.ORCID http://orcid.org/0000-0001-8643-5037
Daijiro HaradaDepartment of Hematology, Oncology and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
Nobuaki OchiDepartment of General Internal Medicine, Kawasaki Medical School, Okayama, Japan.
Masanori FujiiDepartment of Hematology, Oncology and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
Toshio KuboDepartment of Hematology, Oncology and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
Kadoaki OhashiDepartment of Hematology, Oncology and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
Akiko SatoDepartment of Hematology, Oncology and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
Takehiro TanakaDepartment of Pathology, Okayama University Hospital, Okayama, Japan.
Katsuyuki HottaDepartment of Hematology, Oncology and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
Masahiro TabataDepartment of Hematology, Oncology and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
Shinichi ToyookaDepartment of Thoracic, Breast and Endocrinological Surgery, Okayama University Hospital, Okayama, Japan.
Mitsune TanimotoDepartment of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Katsuyuki KiuraDepartment of Hematology, Oncology and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
Okayama University Hospital · JPOkayama University · JPKawasaki Medical School · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malignant mesothelioma is an aggressive and therapy-resistant neoplasm arising from mesothelial cells. Evidence suggests that the major pathology associated with asbestos-induced mesothelioma is local iron overload. In the present study, we induced iron-induced mesothelioma in rats based on previous reports. Ten Wistar rats were given ferric saccharate and nitrilotriacetate i.p. for 5 days a week. Five of the ten rats exhibited widespread mesotheliomas in the peritoneum and tunica vaginalis. The tumor cells showed positive immunostaining for calretinin, wilms tumor-1, podoplanin and the oxidative DNA marker 8-hydroxy-2'-deoxyguanosine. In three of the five rats with mesothelioma, array-based comparative genomic hybridization analysis identified a common chromosomal deletion mapped to the chromosomal 4q31 locus, which encompasses the TBXAS1 gene. Downregulation of the TBXAS1 gene was confirmed using quantitative PCR. TBXAS1 gene expression was also reduced in three of four human malignant pleural mesothelioma cell lines compared with normal bronchial epithelial cells. Immunohistochemistry revealed that TBXAS1 expression was weakly positive and positive in five and three out of eight human malignant mesothelioma samples, respectively. In conclusion, TBXAS1 gene expression was downregulated in rats with iron-induced mesothelioma. The relationship between iron overload and TBXAS1 downregulation should be pursued further.

Indexed as

8-Hydroxy-2'-DeoxyguanosineAnimalsBiomarkers, TumorCalbindin 2Cell Cycle ProteinsCell Line, TumorChromosome DeletionDeoxyguanosineDown-RegulationFerric CompoundsFerric Oxide, SaccharatedGlucaric AcidHumansIronIron OverloadLung Neoplasms8-Hydroxy-2'-DeoxyguanosineBiomarkers, TumorCalbindin 2Cell Cycle ProteinsDeoxyguanosineFerric CompoundsFerric Oxide, SaccharatedGlucaric AcidIronMembrane GlycoproteinsNuclear ProteinsPdpn protein, ratPodoplaninRNA Splicing FactorsThromboxane-A SynthaseWTAP protein, humanAsbestoscarcinogenesisironmalignant mesotheliomaTBXAS1

Identifiers

PMID26211743
PMCPMC4638004
OpenAlexW1909537760

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.